ArticleDiabetes, obesity & metabolism2026
Downstream Treatment Burden and Health-Care Utilization Following Initiation of GLP-1 Receptor Agonists or SGLT2 Inhibitors in Type 2 Diabetes.
Yazan Alhamdan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.